Amphastar Pharmaceuticals (AMPH) Short term Debt (2016 - 2025)
Historic Short term Debt for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $923000.0.
- Amphastar Pharmaceuticals' Short term Debt rose 26626.98% to $923000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $923000.0, marking a year-over-year increase of 26626.98%. This contributed to the annual value of $234000.0 for FY2024, which is 4633.03% down from last year.
- Amphastar Pharmaceuticals' Short term Debt amounted to $923000.0 in Q3 2025, which was up 26626.98% from $927000.0 recorded in Q2 2025.
- Over the past 5 years, Amphastar Pharmaceuticals' Short term Debt peaked at $12.9 million during Q2 2023, and registered a low of $224000.0 during Q1 2025.
- Its 5-year average for Short term Debt is $2.8 million, with a median of $1.7 million in 2022.
- In the last 5 years, Amphastar Pharmaceuticals' Short term Debt soared by 52809.92% in 2023 and then plummeted by 9807.28% in 2024.
- Quarter analysis of 5 years shows Amphastar Pharmaceuticals' Short term Debt stood at $2.2 million in 2021, then surged by 38.33% to $3.0 million in 2022, then tumbled by 85.69% to $436000.0 in 2023, then plummeted by 46.33% to $234000.0 in 2024, then skyrocketed by 294.44% to $923000.0 in 2025.
- Its Short term Debt stands at $923000.0 for Q3 2025, versus $927000.0 for Q2 2025 and $224000.0 for Q1 2025.